Table 3.
Visual acuity change at 3 months, 6 months, 9 months, 15 months, and 2 to 5 years follow-up from initial visit, in those seen within 3 months of onset.
| Follow-up/Initial Visual Acuity | Non-ischemic CRVO (n=374**) |
Ischemic CRVO (as first diagnosis) (n=64**) |
Ischemic CRVO (converted from non-ischemic) (n=43**) |
||||||
|---|---|---|---|---|---|---|---|---|---|
| n | Number (%) of eyes |
n** | Number (%) of eyes |
n** | Number (%) of eyes |
||||
| Improved | Worsened | Improved | Worsened | Improved | Worsened | ||||
| 3 months* | (n=317) | (n=59) | (n=40) | ||||||
| 20/15–20/30 | 135 | 2 (1%) | 18 (13%) | 0 | -- | -- | 0 | -- | -- |
| 20/40–20/60 | 70 | 14 (20%) | 17 (24%) | 0 | -- | -- | 0 | -- | -- |
| 20/70–20/100 | 39 | 6 (15%) | 15 (38%) | 1 | 0 (0%) | 1 (100%) | 0 | -- | -- |
| 20/200–20/400 | 65 | 25 (38%) | 14 (22%) | 13 | 2 (15%) | 7 (54%) | 13 | 0 (0%) | 8 (62%) |
| CF or worse | 8 | 5 (62%) | 0 (0%) | 45 | 4 (9%) | 1 (2%) | 27 | 1 (4%) | 1 (4%) |
| 20/60 or better | 205 | 16 (8%) | 35 (17%) | 0 | -- | -- | 0 | -- | -- |
| 20/70 or worse | 112 | 36 (32%) | 29 (26%) | 59 | 6 (10%) | 9 (15%) | 40 | 1 (2%) | 9 (22%) |
| 6 months* | (n=258) | (n=52) | (n=33) | ||||||
| 20/15–20/30 | 89 | 2 (2%) | 18 (20%) | 0 | -- | -- | 0 | -- | -- |
| 20/40–20/60 | 70 | 17 (24%) | 18 (26%) | 0 | -- | -- | 0 | -- | -- |
| 20/70–20/100 | 37 | 9 (24%) | 15 (41%) | 0 | -- | -- | 0 | -- | -- |
| 20/200–20/400 | 58 | 23 (41%) | 13 (22%) | 11 | 2 (18%) | 6 (55%) | 8 | 0 (0%) | 6 (75%) |
| CF or worse | 4 | 3 (75%) | 1 (25%) | 41 | 6 (15%) | 5 (12%) | 25 | 3 (12%) | 2 (8%) |
| 20/60 or better | 159 | 19 (12%) | 36 (23%) | 0 | -- | -- | 0 | -- | -- |
| 20/70 or worse | 99 | 35 (35%) | 29 (29%) | 52 | 8 (15%) | 11 (21%) | 33 | 3 (9%) | 8 (24%) |
| 9 months* | (n=226) | (n=52) | (n=35) | ||||||
| 20/15–20/30 | 89 | 1 (1%) | 17 (19%) | 0 | -- | -- | 0 | -- | -- |
| 20/40–20/60 | 61 | 12 (20%) | 18 (30%) | 0 | -- | -- | 0 | -- | -- |
| 20/70–20/100 | 28 | 6 (21%) | 14 (50%) | 0 | -- | -- | 0 | -- | -- |
| 20/200–20/400 | 43 | 18 (42%) | 8 (19%) | 11 | 1 (9%) | 7 (64%) | 11 | 1 (9%) | 7 (64%) |
| CF or worse | 5 | 4 (80%) | 0 (0%) | 41 | 7 (17%) | 4 (10%) | 24 | 6 (27%) | 1 (4%) |
| 20/60 or better | 150 | 13 (9%) | 25 (17%) | 0 | -- | -- | 0 | -- | -- |
| 20/70 or worse | 76 | 28 (37%) | 22 (29%) | 52 | 8 (15%) | 11 (21%) | 35 | 7 (20%) | 8 (23%) |
| 15 months* | (n=190) | (n=38) | (n=25) | ||||||
| 20/15–20/30 | 69 | 0 (0%) | 14 (20%) | 0 | -- | -- | 0 | -- | -- |
| 20/40–20/60 | 51 | 13 (25%) | 11 (22%) | 0 | -- | -- | 0 | -- | -- |
| 20/70–20/100 | 29 | 3 (10%) | 15 (52%) | 0 | -- | -- | 0 | -- | -- |
| 20/200–20/400 | 37 | 17 (46%) | 8 (22%) | 6 | 1 (17%) | 4 (67%) | 8 | 2 (25%) | 4 (50%) |
| CF or worse | 4 | 4 (100%) | 0 (0%) | 32 | 9 (28%) | 6 (19%) | 17 | 2 (12%) | 1 (6%) |
| 20/60 or better | 120 | 13 (11%) | 25 (21%) | 0 | -- | -- | 0 | -- | -- |
| 20/70 or worse | 70 | 24 (34%) | 23 (33%) | 38 | 10 (26%) | 10 (26%) | 25 | 4 (16%) | 5 (20%) |
| 2 to 5 years | (n=205) | (n=26) | (n=20) | ||||||
| 20/15–20/30 | 84 | 0 (0%) | 16 (19%) | 0 | -- | -- | 0 | -- | -- |
| 20/40–20/60 | 53 | 16 (30%) | 12 (23%) | 0 | -- | -- | 0 | -- | -- |
| 20/70–20/100 | 25 | 6 (24%) | 10 (40%) | 0 | -- | -- | 0 | -- | -- |
| 20/200–20/400 | 40 | 24 (60%) | 6 (15%) | 6 | 0 (0%) | 4 (67%) | 6 | 2 (33%) | 4 (67%) |
| CF or worse | 3 | 2 (67%) | 0 (0%) | 20 | 6 (30%) | 4 (20%) | 14 | 3 (21%) | 2 (14%) |
| 20/60 or better | 137 | 16 (12%) | 28 (20%) | 0 | -- | -- | 0 | -- | -- |
| 20/70 or worse | 68 | 32 (47%) | 16 (24%) | 26 | 6 (23%) | 8 (31%) | 20 | 5 (25%) | 6 (30%) |
CF = counting fingers; CRVO=Central retinal Vein Occlusion
*
± 6 weeks for 3, 6, and 9 months; ±12 weeks for 15 months
**
Total number of eyes that had at least one follow-up period in which visual acuity change was assessed